To the Editor: Cowie et al. (Sept. 17 issue) 1 report on the results of the Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with ...
On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
Intervention/Treatment: The study tests the ASV therapy using the ResMed AirCurve 11 device. This intervention targets upper airway resistance and respiratory-related arousals, potentially offering a ...
ResMed announced primary results from a multicenter, randomized controlled phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF ...
News-Medical.Net on MSN
New clinical practice guideline provides updated recommendations for treatment of central sleep apnea
A new clinical practice guideline developed by a task force of the American Academy of Sleep Medicine provides updated ...
SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback